Back to search results

Couples Coping Together Against Cancer Program

This study is looking at how helpful and well-received a program called "Couples Coping Together Against Cancer" is for patients and their partners. The program aims to support couples when one partner has cancer, including glioblastoma (a type of brain tumor), breast cancer (including metastatic, meaning it has spread), or lung cancer. You would use a tool called the Connecting Care App, have screenings and educational sessions, and might also have counseling sessions. The researchers want to see how many people join and stay in the program, and how well they stick with it. This study is currently unclear on its recruitment status and plans to enroll 160 participants.

Study design
This is an observational study, meaning participants are observed without receiving a specific experimental treatment. It plans to include 160 participants.
What's involved
You would access the Connecting Care App, undergo biopsychosocial screenings and psychoeducation sessions (30-45 minutes), and complete surveys. You might also receive up to four 30-45 minute counseling sessions.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for retention at 3 and 6 months, and adherence for up to 3 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07664579

Investigating the Feasibility and Acceptability of an Innovative Interdisciplinary Supportive Care Program: Couples Coping Together Against Cancer

Recruiting
Not specifiedAges 18+Observational
City of Hope Medical Center
~160 participants
Updated 2026-06-24 on ClinicalTrials.gov
What's tested:Non-Interventional Study

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Accrual rate (AR)
Measured over Up to 12 months
+3 more outcomes measured

Conditions

Anatomic Stage IV Breast Cancer AJCC v8
Glioblastoma
Lung Carcinoma
Malignant Solid Neoplasm
Metastatic Breast Carcinoma

Explore related trials

Breast CarcinomaGlioblastomaLung CarcinomaSolid Neoplasm

NCT07664579

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • City of Hope Medical Center

    Duarte, Californiastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • William Dale · PRINCIPAL_INVESTIGATOR · City of Hope Medical Center

Who to contact

William Dale
[email protected]
626-256-4673 · ext. 85153
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Have received a diagnosis of a primary brain tumor (glioblastoma), or other cancers (breast, lung, etc.)
Are new patients to City of Hope (COH) (all sites) or receive at least some of their care at City of Hope- Duarte Campus (care is defined as: procedures, consults, laboratories, imaging, surgery, and/or treatment)
The patient is in a committed relationship/partnership with a partner and the partner is available and willing to participate
Are English or Spanish speaking
≥ 18 years of age
Have access to a smartphone, computer/laptop or internet connection to complete all study procedures

Exclusion

Significant cognitive impairment
Inpatient psychiatric treatment for severe mental illness or overt signs of severe psychopathology (e.g., psychosis)
Visual, hearing, voice, or motor impairment that prevents completion of study procedures as evidenced by clinical judgment
Committed partners will be excluded from the study if they:
Refuse to complete informed consent
Have cognitive impairment
Have severe mental illness that would prevent informed consent and completion of study activities as evidenced by clinical judgment

What this trial measures

  • Accrual rate (AR)Up to 12 months

    Defined as number of enrolled dyads/number of eligible dyads x 100. Recruitment rate along with 95% confidence interval (CI) will be calculated. Program will be considered feasible with ≥ 70% recruitment rate.

  • Retention rate (RR)At 3 month and 6 month follow up

    Defined as percentage of dyads retained at the 3-month follow-up. Retention rate along with 95% CI will be calculated. Program will be considered feasible with ≥ 70% retention rate.

  • Adherence rate (AdR)Up to 3 month follow up

    Defined as percentage of dyads who completed all core components of the study at the 3-month follow-up. Adherence rate along with 95% CI will be calculated. Program will be considered feasible with ≥ 70% adherence rate.

  • Study Satisfaction (SS)Up to 6 month follow up

    Defined by the percentage of respondents (patients, partners, providers and staff) who scored positively on various surveys assessing study satisfaction (e.g. agree to strongly agree or helpful to very helpful). A rate of 70% will be considered acceptable Acceptability will be measured using a survey on study satisfaction. Acceptability rate will be computed with 95% CI.